Sage Therapeutics - SAGE Stock Forecast, Price & News

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Wall Street Analyst Weigh In

A number of brokerages have commented on SAGE. Stifel Nicolaus decreased their price objective on Sage Therapeutics from $58.00 to $56.00 in a research report on Tuesday, August 2nd. Citigroup cut their target price on Sage Therapeutics from $41.00 to $40.00 in a report on Wednesday, August 3rd. Mizuho reduced their price objective on shares of Sage Therapeutics from $41.00 to $37.00 in a research note on Wednesday, May 4th. SVB Leerink lowered their target price on shares of Sage Therapeutics from $50.00 to $40.00 and set a "market perform" rating on the stock in a research note on Monday, July 11th. Finally, StockNews.com raised shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, August 3rd. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, Sage Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $54.47.

Sage Therapeutics Price Performance

SAGE Stock traded down $0.58 during trading on Friday, hitting $42.39. The company had a trading volume of 1,278 shares, compared to its average volume of 507,283. The company has a fifty day moving average price of $36.06 and a two-hundred day moving average price of $35.19. Sage Therapeutics has a fifty-two week low of $27.36 and a fifty-two week high of $47.75.

Sage Therapeutics (NASDAQ:SAGE - Get Rating) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($2.13) earnings per share for the quarter, missing the consensus estimate of ($2.12) by ($0.01). Sage Therapeutics had a negative return on equity of 30.10% and a negative net margin of 8,162.17%. The firm had revenue of $1.50 million during the quarter, compared to the consensus estimate of $1.77 million. During the same period in the previous year, the company posted ($1.83) EPS. The firm's revenue for the quarter was down 8.6% compared to the same quarter last year. On average, analysts expect that Sage Therapeutics will post -8.68 earnings per share for the current fiscal year.